Cancer of unknown primary (CUP): Does cause of death and family history implicate hidden phenotypically changed primaries?

Annals of Oncology

Volumn 23, Issue 10, 2012, Pages 2720-2724

  Hemminki, K ^a,b   Bevier, M ^a   Sundquist, J ^b,c   Hemminki, A ^d  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b LUND UNIVERSITY   (Sweden)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Cancer of unknown primary (CUP); Cancer prevention; Epidemiology

Indexed keywords

AGED; ARTICLE; BREAST CANCER; CANCER MORTALITY; CANCER OF UNKNOWN PRIMARY SITE; CANCER PATIENT; CANCER REGISTRY; CANCER RISK; CAUSE OF DEATH; CHILD; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; FAMILY HISTORY; HUMAN; KIDNEY CANCER; LIVER CANCER; LUNG CANCER; MAJOR CLINICAL STUDY; MELANOMA; NERVOUS SYSTEM TUMOR; NONHODGKIN LYMPHOMA; OVARY CANCER; PANCREAS CANCER; PARENT; PHENOTYPE; PRIORITY JOURNAL; PROGENY; PROSTATE CANCER; SIBLING; STOMACH CANCER; SWEDEN; THYROID CANCER;

EID: 84867117709     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds063     Document Type: Article

References (39)

1. Shu X, Sundquist K, Sundquist J, Hemminki K. Time trends in incidence, causes of death, and survival of cancer of unknown primary in Sweden. Eur J Cancer Prev 2011; in press.
2. van de Wouw AJ, Janssen-Heijnen ML, Coebergh JW, Hillen HF. Epidemiology of unknown primary tumours; incidence and population-based survival of 1285 patients in Southeast Netherlands, 1984-1992. Eur J Cancer 2002; 38: 409-413.
3. Hemminki K, Bevier M, Hemminki A, Sundquist J. Survival in cancer of unknown primary site: population-based analysis by site and histology. Ann Oncol 2011; in press.
4. Fizazi K, Greco FA, Pavlidis N, Pentheroudakis G. Cancer of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011; 22: vi64-vi68.
5. Morris GJ, Greco FA, Hainsworth JD et al. Cancer of unknown primary site. Semin Oncol 2010; 37: 71-79.
6. Culine S. Prognostic factors in unknown primary cancer. Semin Oncol 2009; 36: 60-64.
7. Greco FA, Pavlidis N. Treatment for patients with unknown primary carcinoma and unfavorable prognostic factors. Semin Oncol 2009; 36: 65-74.
8. Hemminki K, Liu H, Hemminki A, Sundquist J. Power and limits of modern cancer diagnostics: cancer of unknown primary. Ann Oncol 2012; 23: 760-764.
9. Monzon FA, Koen TJ. Diagnosis of metastatic neoplasms: molecular approaches for identification of tissue of origin. Arch Pathol Lab Med 2010; 134: 216-224.
10. Pentheroudakis G, Greco FA, Pavlidis N. Molecular assignment of tissue of origin in cancer of unknown primary may not predict response to therapy or outcome: a systematic literature review. Cancer Treat Rev 2009; 35: 221-227.
11. Greco FA, Oien K, Erlander M et al. Cancer of unknown primary: progress in the search for improved and rapid diagnosis leading toward superior patient outcomes. Ann Oncol 2011; in press.
12. Daugaard G. Unknown primary tumors. Cancer Treat Rev 1994; 20: 119-147.
13. Freudenberg LS, Rosenbaum-Krumme SJ, Bockisch A et al. Cancer of unknown primary. Recent results. Cancer Res 2008; 170: 193-202.
14. Kramer A, Hubner G, Schneeweiss A et al. Carcinoma of unknown primary-an orphan disease?. Breast Care (Basel) 2008; 3: 164-170.
15. Greco F, Hainsworth JDeVita VJ, Hellman S, Rosenberg S. Cancer of unknown primary site. Cancer: Principles and Practice of Oncology 20119th editionPhiladelphia, PALippincott2033-2051.
16. Pavlidis N, Fizazi K. Carcinoma of unknown primary (CUP). Crit Rev Oncol Hematol 2009; 69: 271-278.
17. van de Wouw AJ, Jansen RL, Speel EJ, Hillen HF. The unknown biology of the unknown primary tumour: a literature review. Ann Oncol 2003; 14: 191-196.
18. Bissell MJ, Labarge MA. Context, tissue plasticity, and cancer: are tumor stem cells also regulated by the microenvironment?. Cancer Cell 2005; 7: 17-23.
19. Eccles SA, Welch DR. Metastasis: recent discoveries and novel treatment strategies. Lancet 2007; 369: 1742-1757.
20. Udagawa T. Tumor dormancy of primary and secondary cancers. APMIS 2008; 116: 615-628.
21. Collado M, Serrano M. Senescence in tumours: evidence from mice and humans. Nat Rev Cancer 2010; 10: 51-57.
22. Bissell MJ, Hines WC. Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat Med 2011; 17: 320-329.
23. Hemminki K, Ji J, Sundquist J, Shu X. Familial risks in cancer of unknown primary: tracking the primary sites. J Clin Oncol 2011; 29: 435-440.
24. Cohen J, Bilsen J, Addington-Hall J et al. Population-based study of dying in hospital in six European countries. Palliat Med 2008; 22: 702-710.
25. Socialstyrelsen. Causes of Death 2010. Stockholm, Sweden: National Board of Health and Welfare 2011; 258.
26. Hemminki K, Ji J, Brandt A et al. The Swedish Family-Cancer Database 2009: prospects for histology-specific and immigrant studies. Int J Cancer 2010; 126: 2259-2267.
27. Shu X, Liu H, Ji J et al. Subsequent cancers in patients diagnosed with cancer of unknown primary (CUP): etiological insights?. Ann Oncol 2011; in press.
28. Brandt A, Sundquist J, Hemminki K. Risk of incident and fatal melanoma in individuals with a family history of incident or fatal melanoma or any cancer. Br J Dermatol 2011; 165: 342-348.
29. Hemminki K, Sundquist J, Brandt A. Familial mortality and familial incidence in cancer. J Clin Oncol 2011; 29: 712-718.
30. Tothill RW, Kowalczyk A, Rischin D et al. An expression-based site of origin diagnostic method designed for clinical application to cancer of unknown origin. Cancer Res 2005; 65: 4031-4040.
31. Varadhachary GR, Talantov D, Raber MN et al. Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation. J Clin Oncol 2008; 26: 4442-4448.
32. Varadhachary GR, Spector Y, Abbruzzese JL et al. Prospective gene signature study using microRNA to identify the tissue of origin in patients with carcinoma of unknown primary. Clin Cancer Res 2011; 17: 4063-4070.
33. Bridgewater J, van Laar R, Floore A, Van TVL. Gene expression profiling may improve diagnosis in patients with carcinoma of unknown primary. Br J Cancer 2008; 98: 1425-1430.
34. Greco FA, Spigel DR, Yardley DA et al. Molecular profiling in unknown primary cancer: accuracy of tissue of origin prediction. Oncologist 2010; 15: 500-506.
35. Horlings HM, van Laar RK, Kerst JM et al. Gene expression profiling to identify the histogenetic origin of metastatic adenocarcinomas of unknown primary. J Clin Oncol 2008; 26: 4435-4441.
36. Monzon FA, Medeiros F, Lyons-Weiler M, Henner WD. Identification of tissue of origin in carcinoma of unknown primary with a microarray-based gene expression test. Diagn Pathol 2010; 5: 3.
37. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011; 331: 1565-1570.
38. Olen K. Pathologic evaluation of unknown primary cancer. Semin Oncol 2009; 36: 8-37.
39. Abumaree M, Al Jumah M, Pace RA, Kalionis B. Immunosuppressive properties of mesenchymal stem cells. Stem Cell Rev 2011; in press.